Release date: 2013-08-06
The Molecular Imaging Center of the Institute of Atomic Medicine of Jiangsu Province cooperated with the National Institute of Health's Molecular Imaging and Nanomedicine Laboratory to successfully develop a new type of tumor PET imaging agent and obtained the national invention patent in China. Recently, a group of lung cancer patients who cooperated with the Fourth People's Hospital of Jiangsu Province and the Fourth People's Hospital of Wuxi City used the new imaging agent to receive PET clinical research results, published in the American Journal of Nuclear Medicine, and was approved by the US Nuclear Medicine. Selected as a popular article with the Molecular Imaging Society.
According to reports, the unique advantages of positron emission tomography (PET) in early diagnosis, staging and efficacy monitoring of tumors have been widely recognized worldwide. In mainland China, more than 80% of provinces, municipalities and autonomous regions have been established. There are more than 100 PET centers. At present, the only PET imaging agent used in China is the sugar metabolism tracer 18F-FDG. The imaging agent utilizes the characteristics of strong metabolism of malignant tumor cells and increased demand for glucose, and reflects the level of glucose metabolism of organs or tissues in the body, thereby realizing tumor diagnosis. With the deepening of research on the pathogenesis of tumors, the researchers found that primary tumors have the ability to induce neovascularization. Their growth and metastasis depend on the formation of tumor angiogenesis, and integrin plays an important role in angiogenesis. In order to "open the key to angiogenesis", the role of αvβ3 is particularly important, and thus it has become the most attractive target for tumor blood vessels. Since the polypeptide containing the sperm-glycan-associated sequence (Arg-Gly-Asp, RGD) can be recognized by the integrin αvβ3 receptor, in recent years, the radionuclide-labeled polypeptide containing the RGD sequence has been shown to be a tumor angiogenesis. The research of imaging agents and therapeutic drugs has become one of the research hotspots of nuclear medicine. The RDF-based PET imaging agent labeled with 18F has been successfully developed abroad, but it is clinically popular due to the harsh, time-consuming, complicated and low yield of the preparation process. There are restrictions in the application.
The Molecular Imaging Center of the Institute of Atomic Medicine of Jiangsu Province cooperated with the National Institutes of Health's Molecular Imaging and Nanomedicine Laboratory to realize the one-step fluorine labeling of RGD peptides by combining 18F ions with metal aluminum to form 18F-aluminum complexes. The preliminary process research and preliminary pharmacokinetic study of the fluorine [18F]-aluminum-piramide peptide kit were completed and obtained the national invention patent. Compared with foreign RGD PET imaging agents, the new imaging agent has better pharmacokinetic properties in vivo, and the reaction time is greatly shortened. The kit and simple labeling process are convenient for clinicians to prepare immediately, which reduces the radioactive operators. Irradiated, it can meet the needs of patients on the go. At the same time, it is optimistic that the product has not only expanded the domestic PET imaging agent variety, but also has a relatively low cost, which helps to expand the beneficiaries.
Source: China Medical Technology Network
Smart Fire Protection System,Fire Alarm System Transmission Device,Fire System Protocol Converter,Protocol Converter Fire Device
LIAONING YINGKOU TIANCHENG FIRE PROTECTION EQUIPMENT CO.,LTD , https://www.tcfiretech.com